New and experimental HIV treatments: latest news

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • Top 10 HIV Clinical Developments of 2017

    By David Alain Wohl, M.D., professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC).

    19 November 2017 | The Body Pro
  • GSK and Gilead go head to head as HIV drugs enter new phase

    Gilead Sciences and GlaxoSmithKline are heading for an HIV showdown, pushing rival treatment visions and competing products that are expected to hit the market in the next few months. Gilead is likely to secure the bigger near-term win, as it builds on a 20-year-old strategy of combining three drugs to control the AIDS virus, while GSK is placing a longer bet that its core drug is potent enough to work with just one other.

    02 November 2017 | Reuters
  • DC biohackers and blockchainers take on HIV

    Tristan Roberts tested a treatment for HIV by self-injecting. Next, Ascendance Biomedical plans to share over the blockchain. It's being done outside the FDA's regulatory process, and a bioethicist has concerns.

    01 November 2017 | Technical.ly DC
  • Antibody-Based HIV Tx Proves Durable

    The monoclonal antibody HIV drug ibalizumab, designed for patients who've developed severe drug resistance, had long-lasting protection in the 24-week extension phase of a phase III trial, researchers reported here.

    10 October 2017 | MedPage Today
  • Bictegravir-Containing Regimen Found to Be Non-Inferior to Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adult Patients with HIV

    Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor (bPI) to a fixed-dose combination of bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone.

    04 October 2017 | Gilead press release
  • The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir

    The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under review in the United States and the European Union as part of a once-daily, single-tablet HIV regimen. The licence allows manufacturers to develop and sell generic medicines containing BIC, if approved in the United States, in 116 low- and middle-income countries where more than 30 million people live with HIV.

    04 October 2017 | Medicines Patent Pool
  • Promising HIV Treatments in Late-Stage Clinical Development

    The following monotherapies and combination regimens are in late-stage clinical development or FDA review.

    02 October 2017 | P&T Community
  • Single-pill HIV treatment to save SA R11bn – health ministry

    A single-pill HIV treatment is expected to be introduced in 2018 and is projected to save SA about R11bn over the following six years, the health ministry announced on Friday.

    25 September 2017 | News24
  • New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price

    A breakthrough pricing agreement has been announced which will accelerate the availability of the first affordable, generic, single-pill HIV treatment regimen containing dolutegravir (DTG) to public sector purchasers in low- and middle-income countries (LMICs) at around US$75 per person, per year.

    22 September 2017 | UNAIDS
  • Immune 'Cocktails' Likely Needed in HIV

    Immunological attack on HIV, whether for prevention or treatment, is likely to have important similarities to current drug therapies, two research papers suggest.

    21 September 2017 | MedPage Today HIV/AIDS
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.